Table 3.
Turnover Rates of T-cell Subsets
| Controls | HIV-2-LV | HIV-2-HV | HIV-1 | P Value | |
|---|---|---|---|---|---|
| Naive T-cells (CD45R0−) | |||||
| CD4+ | |||||
| Peak (%) | 0.34 (0.30–0.79) | 0.61 (0.41–0.79) | 0.53 (0.23–0.93) | 0.45 (0.25–0.85) | .520 |
| p (%/day) | 0.47 (0.34–0.56) | 0.44 (0.11–0.72) | 0.53 (0.20–1.13) | 0.40 (0.23–0.84) | .492 |
| T2 (days) | 148 (124–229) | 142 (92–227) | 137 (69–409) | 173 (83–336) | .806 |
| CD8+ | |||||
| Peak | 0.44 (0.22–0.66) | 0.47 (0.37–0.65) | 0.66 (0.48–0.96) | 0.88 (0.47–1.01) | .019 |
| p (%/day) | 0.30 (0.23–0.52) | 0.38 (0.23–0.80) | 0.66 (0.45–0.99) | 0.69 (0.33–1.61) | .136 |
| T2 (days) | 232 (135–312) | 182 (90–289) | 105 (72–176) | 100 (43–210) | .182 |
| Memory T-cells (CD45RA−) | |||||
| CD4+ | |||||
| Peak (%) | 1.08 (0.77–1.70) | 1.46 (1.22–1.94) | 2.32 (1.12–3.57) | 1.85 (1.33–3.73) | .028 |
| p (%/day) | 1.30 (1.00–2.47) | 1.98 (1.30–2.50) | 1.87 (1.57–6.72) | 2.36 (1.52–5.19) | .047 |
| T2 (days) | 54 (28–72) | 35 (28–53) | 37 (10–44) | 29 (13–46) | .055 |
| CD8+ | |||||
| Peak (%) | 0.85 (0.58–1.47) | 1.50 (0.97–1.82) | 2.65 (1.47–5.02) | 1.60 (1.00–3.34) | .008 |
| p (%/day) | 1.55 (0.71–2.06) | 1.85 (1.20–2.29) | 3.44 (2.44–7.11) | 2.24 (1.10–5.27) | .010 |
| T2 (days) | 45 (35–98) | 38 (30–58) | 20 (9–28) | 32 (13–63) | .031 |
Peak is the maximum level of isotope labeling, corrected for glucose enrichment to derive an equivalent for 1 day's labeling; p, modeled proliferation rate constant; T2, doubling time of cells, within that pool, calculated as ln(2)/p. Values are median (IQR). P values by ANOVA; for T2 data was log-transformed.
Abbreviations: ANOVA, analysis of variance; HIV, human immunodeficiency virus; HIV-2-HV, HIV-2 infected with high viral load (>1000 copies/mL); HIV-2-LV, HIV-2 infected with low viral load (<100 copies/mL); IQR, interquartile range.